The new antiarrhythmic drug vernakalant: ex vivo study of human atrial tissue from sinus rhythm and chronic atrial fibrillation.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Cardiovascular Research

• Publication date

  2013-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/cvr/cvt006PMID 23341576
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparison of electrophysiological and antiarrhythmic effects of vernakalant, ranolazine, and sotalol in canine pulmonary vein sleeve preparations.

  2012cited by this paper
• Rate-Dependent Effects of Vernakalant in the Isolated Non-Remodeled Canine Left Atria Are Primarily Due to Block of the Sodium Channel: Comparison With Ranolazine and dl-Sotalol

  2012cited by this paper
• A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation.

  2011cited by this paper
• Altered Na(+) currents in atrial fibrillation effects of ranolazine on arrhythmias and contractility in human atrial myocardium.

  2010cited by this paper
• Inhibition of IK,ACh current may contribute to clinical efficacy of class I and class III antiarrhythmic drugs in patients with atrial fibrillation

  2010cited by this paper
• Pharmacokinetics of Novel Atrial‐Selective Antiarrhythmic Agent Vernakalant Hydrochloride Injection (RSD1235): Influence of CYP2D6 Expression and Other Factors

  2009cited by this paper
• Vernakalant Hydrochloride for the Rapid Conversion of Atrial Fibrillation After Cardiac Surgery: A Randomized, Double-Blind, Placebo-Controlled Trial

  2009cited by this paper
• Role of potassium currents in cardiac arrhythmias.

  2008cited by this paper
• Pathology‐specific effects of the IKur/Ito/IK,ACh blocker AVE0118 on ion channels in human chronic atrial fibrillation

  2008cited by this paper
• Vernakalant Hydrochloride for Rapid Conversion of Atrial Fibrillation: A Phase 3, Randomized, Placebo-Controlled Trial

  2008cited by this paper
• Inward rectifier potassium currents as a target for atrial fibrillation therapy.

  2008cited by this paper
• Blockade of atrial-specific K+-currents increases atrial but not ventricular contractility by enhancing reverse mode Na+/Ca2+-exchange.

  2007cited by this paper
• Vernakalant (RSD1235): a novel, atrial-selective antifibrillatory agent

  2007cited by this paper
• Atrium-Selective Sodium Channel Block as a Strategy for Suppression of Atrial Fibrillation: Differences in Sodium Channel Inactivation Between Atria and Ventricles and the Role of Ranolazine

  2007cited by this paper
• The Molecular Basis of High-Affinity Binding of the Antiarrhythmic Compound Vernakalant (RSD1235) to Kv1.5 Channels

  2007cited by this paper
• The Effect of Vernakalant (RSD1235), an Investigational Antiarrhythmic Agent, on Atrial Electrophysiology in Humans

  2007cited by this paper
• Specific serine proteases selectively damage KCNH2 (hERG1) potassium channels and I(Kr).

  2006cited by this paper
• RSD1235 blocks late INa and suppresses early afterdepolarizations and torsades de pointes induced by class III agents.

  2006cited by this paper
• AVE0118, Blocker of the Transient Outward Current (Ito) and Ultrarapid Delayed Rectifier Current (IKur), Fully Restores Atrial Contractility After Cardioversion of Atrial Fibrillation in the Goat

  2006cited by this paper
• Human Atrial Ion Channel and Transporter Subunit Gene-Expression Remodeling Associated With Valvular Heart Disease and Atrial Fibrillation

  2005cited by this paper
• Risperidone-induced action potential prolongation is attenuated by increased repolarization reserve due to concomitant block of ICa,L

  2005cited by this paper
• The Mechanism of Atrial Antiarrhythmic Action of RSD1235

  2005cited by this paper
• The G Protein–Gated Potassium Current IK,ACh Is Constitutively Active in Patients With Chronic Atrial Fibrillation

  2005cited by this paper
• Consequences of atrial electrical remodeling for the anti-arrhythmic action of class IC and class III drugs.

  2005cited by this paper
• Role of IKur in Controlling Action Potential Shape and Contractility in the Human Atrium: Influence of Chronic Atrial Fibrillation

  2004cited by this paper
• Blockade of the Inward Rectifying Potassium Current Terminates Ventricular Fibrillation in the Guinea Pig Heart

  2003cited by this paper
• Remodeling of cardiomyocyte ion channels in human atrial fibrillation

  2003cited by this paper
• Molecular Basis of Downregulation of G-Protein–Coupled Inward Rectifying K+ Current (IK,ACh) in Chronic Human Atrial Fibrillation: Decrease in GIRK4 mRNA Correlates With Reduced IK,ACh and Muscarinic Receptor–Mediated Shortening of Action Potentials

  2001cited by this paper
• Cellular Mechanisms of Depressed Atrial Contractility in Patients With Chronic Atrial Fibrillation

  2001cited by this paper
• Molecular basis of functional voltage‐gated K+ channel diversity in the mammalian myocardium

  2000cited by this paper
• Ionic mechanisms of electrical remodeling in human atrial fibrillation.

  1999cited by this paper
• Atrial L-type Ca2+ currents and human atrial fibrillation.

  1999cited by this paper
• Ionic targets for drug therapy and atrial fibrillation-induced electrical remodeling: insights from a mathematical model.

  1999cited by this paper
• Differences between outward currents of human atrial and subepicardial ventricular myocytes.

  1996cited by this paper
• Transient outward and delayed rectifier currents in canine atrium: properties and role of isolation methods.

  1996cited by this paper
• The cardiac arrhythmia suppression trial. Casting suppression in a different light.

  1995cited by this paper
• Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats.

  1995cited by this paper
• Effects of E-4031, almokalant and tedisamil on postrest action potential duration of human papillary muscles.

  1994cited by this paper
• Effects of the New Class III Antiarrhythmic Drug E‐4031 on Myocardial Contractility and Electrophysiological Parameters

  1991cited by this paper
• Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.

  1991cited by this paper
• Classification of antidysrhythmic drugs.

  1975cited by this paper
• Classification of antidysrhythmic drugs.

  1975cited by this paper

• Beneficial effects of doxycycline on atrial electrical remodelling in a rat model of atrial fibrillation

  2025influential citation
• Rational design, synthesis, and evaluation of novel polypharmacological compounds targeting NaV1.5, KV1.5, and K2P channels for atrial fibrillation

  2025cites this paper
• Preparation of Human Atrial Trabeculae for Ex Vivo Analysis of Human Myocardial Function.

  2025cites this paper
• In silico cardiac safety profile of drugs and their potential to induce clinical cardiotoxicity.

  2025cites this paper
• Mechanistic Insights into Sex Differences in Atrial Electrophysiology and Arrhythmia Vulnerability through Sex-specific Computational Models

  2025cites this paper
• Mechanistic insights into sex differences in atrial electrophysiology and arrhythmia vulnerability through sex-specific computational models.

  2025cites this paper
• The modernized classification of cardiac anti-arrhythmic drugs: its application to clinical practice.

  2025cites this paper
• A novel ionic model for matured and paced atrial-like human iPSC-CMs integrating IKur and IKCa currents

  2024cites this paper
• A novel ionic model for matured and paced atrial–like hiPSC–CMs integrating IKur and IKCa currents

  2024cites this paper
• Cardiac arrhythmogenesis: roles of ion channels and their functional modification

  2024cites this paper
• Clinically approved representative small-molecule drugs for cardiopathy therapy.

  2024cites this paper
• In Silico TRials guide optimal stratification of ATrIal FIbrillation patients to Catheter Ablation and pharmacological medicaTION: the i-STRATIFICATION study

  2024cites this paper
• Chamber-specific contractile responses of atrial and ventricular hiPSC-cardiomyocytes to GPCR and ion channel targeting compounds: A microphysiological system for cardiac drug development.

  2024cites this paper
• Resting membrane potential is less negative in trabeculae from right atrial appendages of women, but action potential duration does not shorten with age.

  2023cites this paper
• A critical role of retinoic acid concentration for the induction of a fully human-like atrial action potential phenotype in hiPSC-CM

  2023cites this paper
• A dynamic clamping approach using in silico IK1 current for discrimination of chamber-specific hiPSC-derived cardiomyocytes

  2023cites this paper
• PITX2 Knockout Induces Key Findings of Electrical Remodeling as Seen in Persistent Atrial Fibrillation

  2023cites this paper
• A critical role of retinoic acid concentration for the induction of a fully human-like atrial phenotype in hiPSC-CM

  2023cites this paper
• JAK2 as a surface marker for enrichment of human pluripotent stem cells-derived ventricular cardiomyocytes

  2023cites this paper
• Utilizing human induced pluripotent stem cells to study atrial arrhythmias in the short QT syndrome

  2023cites this paper
• What determines the optimal pharmacological treatment of atrial fibrillation? Insights from in silico trials in 800 virtual atria

  2023cites this paper
• High-throughput longitudinal electrophysiology screening of mature chamber-specific hiPSC-CMs using optical mapping

  2023cites this paper
• Advances in basic and translational research in atrial fibrillation

  2023influential citation
• Integrative human atrial modelling unravels interactive protein kinase A and Ca2+/calmodulin-dependent protein kinase II signalling as key determinants of atrial arrhythmogenesis

  2022cites this paper
• Mechanisms of spontaneous Ca2+ release‐mediated arrhythmia in a novel 3D human atrial myocyte model: I. Transverse‐axial tubule variation

  2022cites this paper
• Antiarrhythmic Effects of Vernakalant in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes from a Patient with Short QT Syndrome Type 1

  2022influential citation
• Mechanisms underlying pro-arrhythmic abnormalities arising from Pitx2-induced electrical remodelling: an in silico intersubject variability study

  2021cites this paper
• Peptide Inhibitors of Kv1.5: An Option for the Treatment of Atrial Fibrillation

  2021influential citation
• Artificial Intelligence-Driven Algorithm for Drug Effect Prediction on Atrial Fibrillation: An in silico Population of Models Approach

  2021cites this paper
• Arrhythmias

  2021cites this paper
• New Strategies for the Treatment of Atrial Fibrillation

  2021influential citation
• A Comparison of Regional Classification Strategies Implemented for the Population Based Approach to Modelling Atrial Fibrillation

  2021cites this paper
• Statistical Approach to Incorporating Experimental Variability into a Mathematical Model of the Voltage-Gated Na+ Channel and Human Atrial Action Potential

  2021cites this paper
• Atrial-specific hiPSC-derived cardiomyocytes in drug discovery and disease modeling.

  2021cites this paper
• Depolarization of the atrial resting membrane potential as an approach to enhance anti-atrial fibrillation efficacy of sodium channel blockers.

  2021cites this paper
• Are atrial human pluripotent stem cell-derived cardiomyocytes ready to identify drugs that beat atrial fibrillation?

  2021cites this paper
• Reply to ‘Are atrial human pluripotent stem cell-derived cardiomyocytes ready to identify drugs that beat atrial fibrillation?’

  2021cites this paper
• Bi-atrial high-density mapping reveals inhibition of wavefront turning and reduction of complex propagation patterns as main antiarrhythmic mechanisms of vernakalant

  2021cites this paper
• Caveolin3 Stabilizes McT1-Mediated Lactate/Proton Transport in Cardiomyocytes.

  2021cites this paper
• Systematic Review and Meta-analysis Appraising Efficacy and Safety of Vernakalant for Cardioversion of Recent-onset Atrial Fibrillation.

  2020cites this paper
• The SK Channel Inhibitors NS8593 and UCL1684 Prevent the Development of Atrial Fibrillation via Atrial-selective Inhibition of Sodium Channel Activity.

  2020cites this paper
• Vernakalant hydrochloride for the treatment of atrial fibrillation: evaluation of its place in clinical practice.

  2020cites this paper
• Intermittent optogenetic tachypacing of atrial engineered heart tissue induces only limited electrical remodelling.

  2020cites this paper
• Investigational Anti–Atrial Fibrillation Pharmacology and Mechanisms by Which Antiarrhythmics Terminate the Arrhythmia: Where Are We in 2020?

  2020cites this paper
• Generating ring-shaped engineered heart tissues from ventricular and atrial human pluripotent stem cell-derived cardiomyocytes

  2020cites this paper
• Revisiting Antiarrhythmic Drug Therapy for Atrial Fibrillation: Reviewing Lessons Learned and Redefining Therapeutic Paradigms

  2020cites this paper
• Dynamics of propagation patterns and anti-arrhythmic mechanisms during atrial fibrillation

  2019cites this paper
• Disease modeling of a mutation in α‐actinin 2 guides clinical therapy in hypertrophic cardiomyopathy

  2019cites this paper
• Vernakalant in Atrial Fibrillation: A Relatively New Weapon in the Armamentarium Against an Old Enemy

  2019cites this paper
• Mechanisms of Antifibrillatory Agents for Atrial Fibrillation

  2019cites this paper
• Human Heart Cardiomyocytes in Drug Discovery and Research: New Opportunities in Translational Sciences.

  2019cites this paper
• Production of hiPSC-derived atrial cardiomyocytes to study the contribution of the KCNN3 variants to lone atrial fibrillation

  2019cites this paper
• Maastricht antiarrhythmic drug evaluator (MANTA): a computational tool for better understanding of antiarrhythmic drugs.

  2019cites this paper
• Human Induced Pluripotent Stem Cell–Derived Engineered Heart Tissue as a Sensitive Test System for QT Prolongation and Arrhythmic Triggers

  2018cites this paper
• Vernakalant does not alter early repolarization or contractility in normal and electrically remodelled atria

  2018influential citation
• Emerging pharmacotherapies for the treatment of atrial fibrillation

  2018cites this paper
• Inhibition of Small Conductance Calcium-Activated Potassium (SK) Channels Prevents Arrhythmias in Rat Atria During β-Adrenergic and Muscarinic Receptor Activation

  2018cites this paper
• Cardiovascular pharmacology of K2P17.1 (TASK-4, TALK-2) two-pore-domain K+ channels

  2018cites this paper
• Sex differences in cardiac electrophysiology.

  2018cites this paper
• German Cardiac Society Working Group on Cellular Electrophysiology state-of-the-art paper: impact of molecular mechanisms on clinical arrhythmia management

  2018cites this paper
• Study the Effects of Vernakalant on Ischemic-Reperfusion Dysrhythmias in Experimental Animals in Comparison with Amiodarone

  2018cites this paper
• University of Birmingham German Cardiac Society Working Group on Cellular Electrophysiology state-of-the-art paper

  2018cites this paper
• Termination of Vernakalant-Resistant Atrial Fibrillation by Inhibition of Small-Conductance Ca2+-Activated K+ Channels in Pigs

  2017cites this paper
• Human iPSC-derived cardiomyocytes cultured in 3D engineered heart tissue show physiological upstroke velocity and sodium current density

  2017cites this paper
• Shape Theoretic and Machine Learning Based Methods for Automatic Clustering and Classification of Cardiomyocytes Based on Action Potential Morphology

  2017cites this paper
• Atrial Fibrillation Dynamics and Ionic Block Effects in Six Heterogeneous Human 3D Virtual Atria with Distinct Repolarization Dynamics

  2017cites this paper
• Biophysical modelling of functional impacts of potassium channel mutations on human atrial and ventricular dynamics

  2017cites this paper
• Late INa Inhibition as an Antiarrhythmic Strategy

  2017cites this paper
• Antiarrhythmic effect of vernakalant in electrically remodeled goat atria is caused by slowing of conduction and prolongation of postrepolarization refractoriness.

  2016cites this paper
• Ranolazine and Vernakalant Prevent Ventricular Arrhythmias in an Experimental Whole‐Heart Model of Short QT Syndrome

  2016cites this paper
• Effects of Potassium Channel Blockers

  2016cites this paper
• Influences of rapid pacing-induced electrical remodeling on pharmacological manipulation of the atrial refractoriness in rabbits.

  2016cites this paper
• Effects of 6-epi-ophiobolin on mechanical and physiological parameters of cardiomyocytes and on the reorganization and amounts of their kv4.x ion channels

  2016cites this paper
• Mechanism of Proarrhythmic Effects of Potassium Channel Blockers.

  2016cites this paper
• Modeling Human Atrial Patho-Electrophysiology from Ion Channels to ECG - Substrates, Pharmacology, Vulnerability, and P-Waves

  2016influential citation
• Refractoriness in human atria: Time and voltage dependence of sodium channel availability.

  2016influential citation
• Kv1.5 Inhibitors for Treatment of Atrial Fibrillation: A Tradeoff between Selectivity and Non-selectivity.

  2016cites this paper
• Balance between sodium and calcium currents underlying chronic atrial fibrillation termination: An in silico intersubject variability study

  2016cites this paper
• Atria are More Sensitive Than Ventricles to GS-458967-Induced Inhibition of Late Sodium Current

  2015cites this paper
• Treatment of Atrial Fibrillation and Atrial Flutter

  2015cites this paper
• Interaction of DPP10a with Kv4.3 channel complex results in a sustained current component of human transient outward current Ito

  2015cites this paper
• [Vernakalant for the conversion of atrial fibrillation of recent onset].

  2015cites this paper
• Vernakalant en la reversión de la fibrilación auricular de reciente comienzo

  2015cites this paper
• In silico investigation of short QT syndrome-linked potassium channel mutations on electro-mechanical function of human atrial cells

  2015cites this paper
• Hot topics and networks in Cardiovascular Research.

  2015cites this paper
• Inhibition of IKr potentiates development of atrial-selective INa block leading to effective suppression of atrial fibrillation.

  2015cites this paper
• Antiarrhythmic principle of SK channel inhibition in atrial fibrillation.

  2015cites this paper
• Atrial-like cardiomyocytes from human pluripotent stem cells are a robust preclinical model for assessing atrial-selective pharmacology

  2015influential citation
• Understanding the cellular mode of action of vernakalant using a computational model: answers and new questions

  2015influential citation
• [New developments in the antiarrhythmic therapy of atrial fibrillation].

  2014cites this paper
• RANOLAZINE IN ATRIAL FIBRILLATION Table I . Cardiac Disorders Associated with an Increase of the Late Sodium Current Myocardial ischemia Heart failure ( systolic and diastolic ) Postmyocardial infarction remodeling Left ventricle hypertrophy Atrial fibrillation Long QT syndrome

  2014cites this paper
• Inhibition of cardiac two-pore-domain K+ (K2P) channels--an emerging antiarrhythmic concept.

  2014cites this paper
• Multiscale analysis of atrial fibrillation mechanisms

  2014cites this paper
• Expanding role of SK channels in cardiac electrophysiology.

  2014cites this paper
• Electrophysiological and Hemodynamic Effects of Vernakalant and Flecainide During Cardiac Resynchronization in Dyssynchronous Canine Hearts

  2014cites this paper
• Atrial-selective antiarrhythmic activity by vernakalant fact or fiction?

  2014cites this paper
• Fibrillation Initiation , Maintenance , and Progression

  2014cites this paper
• Inhibition of cardiac two-pore-domain K+ (K2P) channels by the antiarrhythmic drug vernakalant--comparison with flecainide.

  2014cites this paper
• Ranolazine as a Promising Treatment Option for Atrial Fibrillation: Electrophysiologic Mechanisms, Experimental Evidence, and Clinical Implications

  2014cites this paper
• Vernakalant for the Conversion of Atrial Fibrillation: The New Kid On the Block?

  2014cites this paper